Nautilus Biotechnology, Inc. Cash Flow Statement

Cash Flow Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Depreciation and Depletion 0.71M1.02M1.22M1.85M2.00M
Share-based Compensation 0.37M7.93M10.38M12.14M12.70M
Gains from Investment Securities -0.01M29.89M1.69M7.62M-0.08M
Cash from Operations -14.00M-39.24M-45.81M-51.71M-59.15M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 1.64M1.82M2.20M3.86M4.38M
Depreciation & Amortization (CF) 0.71M1.02M1.22M1.85M2.00M
Change in Working Capital
Change in Account Payables 0.12M1.26M-0.56M0.39M-0.58M
Change in Accured Expenses 0.69M2.25M0.41M0.42M-1.40M
Other Working Capital Changes -1.58M2.75M-1.39M-3.21M-4.15M
Investing Activities
Capital Expenditures 0.92M2.27M2.32M2.44M2.12M
Acquisitions 0.76M
Change in Acquisitions & Divestments 44.00M85.10M163.18M71.60M155.41M
Cash from Investing Activities -25.28M-138.96M-25.74M-43.73M66.25M
Financing Activities
Other financing activities 8.13M
Cash from Financing Activities 75.90M327.45M0.56M0.37M1.14M
Additional items
Change in Cash 36.62M149.24M-70.98M-95.08M8.25M
Free Cash Flow -14.92M-41.51M-48.13M-54.15M-61.27M
Net Cash Flow 36.62M149.24M-70.98M-95.08M8.25M